External broker reports(aggregated public sources), Ord Minnett

Ord Minnett

Ord Minnett is a leading Australian wealth management group, incorporating full-service stockbroking, financial planning and funds management. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>With the timing of the Philips reseller agreement weighing on investors, we believe 4DX’s improving US commercialisation trajectory is being underappreciated.</li><li>The company’s CT LVAS product has been granted reimbursement at US$650 per scan – well ahead of expectations on both timing and quantum (2.2x XV LVAS reimbursement).</li><li>This represents a step- change in 4DX’s unit economics and is likely to see CT LVAS repositioned as its core/front-line screening product (underpinned by higher reimbursement, broader CT utilisation tailwinds). </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

With the timing of the Philips reseller agreement weighing on investors, we believe 4DX’s improving US commercialisation trajectory is being underappreciated.The company’s CT LVAS product has been granted reimbursement at US$650 per scan – well ahead of expectations on both timing and quantum (2.2x XV LVAS reimbursement).This represents a step- change in 4DX’s unit economics and is likely to see CT LVAS repositioned as its core/front-line screening product (underpinned by higher reimbursement, broader CT utilisation tailwinds). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

4DMedical

4DMedical - Pricing Step-Change